We are live on
!
Find out more
Handelsbanken Fonder Portfolio holdings
AUM
$35.1B
1-Year Est. Return
47.76%
This Fund
S&P 500
This Quarter
Est. Return
+2.36%
1 Year Est. Return
+47.76%
3 Year Est. Return
+137.96%
5 Year Est. Return
+170.36%
10 Year Est. Return
+934.7%
AUM
$26.2B
AUM Growth
+$914M
(+3.6%)
Cap. Flow
+$1.01B
Cap. Flow
% of AUM
3.87%
Top 10 Holdings %
Top 10 Hldgs %
32.55%
Holding
1,591
New
69
Increased
817
Reduced
431
Closed
49
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$107M |
| 2 |
EXL Service
EXLS
|
+$72M |
| 3 |
Apple
AAPL
|
+$64.3M |
| 4 |
Synopsys
SNPS
|
+$56.8M |
| 5 |
ServiceNow
NOW
|
+$54.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Halozyme
HALO
|
+$74.5M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$53.5M |
| 3 |
Edwards Lifesciences
EW
|
+$45M |
| 4 |
Abbott
ABT
|
+$40.3M |
| 5 |
Rockwell Automation
ROK
|
+$39.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.4% |
| 2 | Healthcare | 16.63% |
| 3 | Financials | 12.04% |
| 4 | Communication Services | 9.47% |
| 5 | Industrials | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1251
Revolve Group
RVLV
$1.72B
| $546K | ﹤0.01% |
16,300
| – | – |
|
1252
Aurinia Pharmaceuticals
AUPH
$2.02B
| $545K | ﹤0.01% |
60,700
| – | – |
|
1253
Iovance Biotherapeutics
IOVA
$2.95B
| $538K | ﹤0.01% |
72,700
-2,100
| -3% | -$19.5K |
|
1254
UFP Technologies
UFPT
$2.48B
| $538K | ﹤0.01% |
+2,200
| New | +$640K |
|
1255
Clarivate
CLVT
$1.25B
| $537K | ﹤0.01% |
105,700
-8,400
| -7% | -$48.4K |
|
1256
Amphastar Pharmaceuticals
AMPH
$858M
| $535K | ﹤0.01% |
14,400
-2,500
| -15% | -$114K |
|
1257
Integra LifeSciences
IART
$1.42B
| $535K | ﹤0.01% |
23,602
| – | – |
|
1258
ADT
ADT
$5.46B
| $534K | ﹤0.01% |
77,300
+400
| +0.5% | +$2.91K |
|
1259
Celldex Therapeutics
CLDX
$3.35B
| $533K | ﹤0.01% |
21,100
+7,300
| +53% | +$198K |
|
1260
Green Brick Partners
GRBK
$3.04B
| $531K | ﹤0.01% |
9,400
+400
| +4% | +$28.4K |
|
1261
Dyne Therapeutics
DYN
$4.85B
| $530K | ﹤0.01% |
22,500
+3,200
| +17% | +$94.7K |
|
1262
Victory Capital Holdings
VCTR
$7.27B
| $530K | ﹤0.01% |
8,100
+1,600
| +25% | +$101K |
|
|
HTO
1263
H2O America
HTO
$2.65B
| $527K | ﹤0.01% |
10,704
-216
| -2% | -$11.9K |
|
1264
Criteo S.A. Ordinary Shares
CRTO
$915M
| $526K | ﹤0.01% |
13,300
| – | – |
|
|
DEA
1265
Easterly Government Properties
DEA
$1.18B
| $526K | ﹤0.01% |
18,520
+7,400
| +67% | +$235K |
|
1266
Bausch Health
BHC
$2.37B
| $525K | ﹤0.01% |
65,100
+10,100
| +18% | +$83.3K |
|
|
PINC
1267
DELISTED
Premier
PINC
| $524K | ﹤0.01% |
24,695
-16,600
| -40% | -$352K |
|
1268
Tecnoglass Holdings Inc.
TGLS
$1.87B
| $524K | ﹤0.01% |
6,600
| – | – |
|
1269
Vestis
VSTS
$1.79B
| $520K | ﹤0.01% |
+34,100
| New | +$513K |
|
1270
Immunovant
IMVT
$8.64B
| $518K | ﹤0.01% |
20,900
| – | – |
|
|
UCTT
1271
Ultra Clean Holdings
UCTT
$4.21B
| $518K | ﹤0.01% |
14,400
-3,800
| -21% | -$141K |
|
1272
Atlanta Braves Holdings Series B
BATRK
$3.41B
| $516K | ﹤0.01% |
13,477
-900
| -6% | -$35.9K |
|
1273
CleanSpark
CLSK
$2.96B
| $516K | ﹤0.01% |
56,000
| – | – |
|
1274
First Financial Bancorp
FFBC
$3.6B
| $516K | ﹤0.01% |
19,184
| – | – |
|
1275
Upwork
UPWK
$1.08B
| $515K | ﹤0.01% |
31,500
-8,700
| -22% | -$125K |
|
Similar funds
GAM
Handelsbanken Fonder's Q4 2024 Portfolio in Review
As of Q4 2024, Handelsbanken Fonder held 1,591 positions worth $26.2B, up 3.6% from $25.3B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Handelsbanken Fonder deployed $1.01B of net new capital in Q4 2024, opening 69 new positions and adding to 817 existing holdings. Its largest new stake was GE Vernova: 105,537 shares worth $34.7M.
By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 35% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Halozyme, an estimated $74.5M trimmed.
- Handelsbanken Fonder's largest Q4 2024 buy was GE Vernova: 105,537 shares worth $34.7M.
- Handelsbanken Fonder added most to Microsoft in Q4 2024, an estimated $107M increase.
- Handelsbanken Fonder's biggest Q4 2024 reduction was Halozyme, cutting an estimated $74.5M.
- Handelsbanken Fonder fully exited BeOne Medicines Ltd in Q4 2024, selling an estimated $5.92M.
- Handelsbanken Fonder's ten largest holdings make up 33% of its $26.2B portfolio in Q4 2024.
- Handelsbanken Fonder opened 69 new positions and closed 49 in Q4 2024.
- Handelsbanken Fonder's portfolio value rose 3.6% quarter-over-quarter to $26.2B.
Based on Handelsbanken Fonder's 13F filing for Q4 2024, filed 3 Feb 2025.